In 2022, two patients died of acute liver failure after receiving Novartis’s gene therapy Zolgensma, which treats spinal muscular atrophy, another rare genetic disorder.

A young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy ...

Tragedy has struck during an important Pfizer medical trial, when a young boy suffered a fatal sudden cardiac arrest after receiving experimental gene therapy — a death that's sent scientists ...

The FDA is assessing the need for “further regulatory action” on Sarepta's Duchenne muscular dystrophy gene therapy in the ...

Sarepta Therapeutics has temporarily suspended use of the gene therapy Elevidys in non-ambulatory patients with Duchenne muscular dystrophy (DMD) after a second patient taking the drug died from ...

Sarepta Therapeutics said a second patient had died after receiving its $3.2 million gene therapy to treat Duchenne muscular dystrophy.

The government has suspended a Seattle company's gene therapy study _ and is reviewing the safety of 28 others around the country _ after learning that a patient died this week.

Sarepta Therapeutics Inc. misled investors about the safety and prospects for one of its Duchenne muscular dystrophy ...

A patient has died after receiving the high dose of Neurogene’s Rett syndrome gene therapy candidate.. The biotech had disclosed the adverse event Nov. 11, and explained the patient was in ...

U.S. health officials say a patient died while participating in a gene therapy experiment to treat arthritis. The precise cause of death is unknown, The Washington Post said Friday. The Food and ...

A second patient with X-linked myotubular myopathy (XLMTM) has died after receiving a high dose of Audentes Therapeutics' investigational gene therapy product, AT132, as part of the ASPIRO ...